Episode 198 - October 2, 2026

The biotech sector maintains strong year-to-date performance despite recent market choppiness and macroeconomic uncertainty, with the XBI index significantly outperforming broader benchmarks. Key industry developments include a major collaboration between Regeneron and Sanofi to extend their Dupixent lifecycle, and a strategic $2 billion equity investment by AstraZeneca into Summit Therapeutics to advance their PD-1/VEGF bispecific pipeline. Clinical data readouts remain a primary driver of volatility, exemplified by the mixed reception of DYN Therapeutics’ DM1 data and the significant market impact of Unicure’s Huntington’s disease gene therapy results. Meanwhile, the obesity and diabetes space continues to evolve rapidly, highlighted by Eli Lilly’s promising data for retatrutide and amylin combinations, which demonstrate substantial weight loss potential despite high discontinuation rates. These events underscore a broader trend of high-stakes binary outcomes and intense competition for novel therapeutic modalities.